Theranos Intarcia Moderna - Three Unicorns of the Apocalypse

Discussion in 'Biotech Startups' started by Milly Vanilly, Jul 7, 2017 at 5:35 AM.

Tags: Add Tags
  1. Beware my friends of the madness of crowds and popular delusions. Hidden in plain sight the Three Unicorns of the Apocalypse have kept their strategies, accomplishments, and finances in the dark world of the "Private Biotech Unicorn"...

    Why did Theranos destroy the reputations of the folks working there ? Super popular with all of the smart people who knew this was the next big thing. CEO with huge press following, Magical technology that would disrupt the diagnostic market. One explosion of fraud later...

    Is the time bomb ticking on all Three Unicorns of the Apocalypse ? Lots of job postings - are these actually invitations to the end of the world ?
     

  2. anonymous

    anonymous Guest

    Interviews have been rush then wait then rush then quiet. Dont know what is happening. Have you heard ?
     
  3. anonymous

    anonymous Guest

    Moderna is a house of cards. They have churned through Sr. Management like hot dogs from a Fenway Park vendor at a home game.. CEO is an Ass who has a history of bold promises that don't pan out, has no scientific background and treats his people mostly like crap. I say mostly because he has pet project people that he rewards. Fidelity just slashed estimates on valuation and any investor post 2015 that thinks they are making money is delusional.
     
  4. Squaring Venture Capital Valuations with Reality
    Stanford University Graduate School of Business Research Paper No. 17-29

    54 Pages Posted: 22 Apr 2017 Last revised: 16 Jul 2017

    Will Gornall
    University of British Columbia (UBC) - Sauder School of Business

    Ilya A. Strebulaev
    Stanford University - Graduate School of Business; National Bureau of Economic Research

    Date Written: July 11, 2017

    Abstract
    We develop a financial model to estimate the fair value of venture capital-backed companies and of each type of security these companies issue. Our model uses the most recent financing round price and the terms of that financing to infer the value of each of their shares. Using data from legal filings, we show that the average highly-valued venture capital-backed company reports a valuation 49% above its fair value, with common shares overvalued by 59%. In our sample of unicorns – companies with reported valuation above $1 billion – almost one half (53 out of 116) lose their unicorn status when their valuation is recalculated and 11 companies are overvalued by more than 100%. Overvaluation arises because the reported valuations assume all of a company’s shares have the same price as the most recently issued shares. In practice, these most recently issued shares almost always have better cash flow rights than the previously issued shares, so equating their prices significantly inflates valuations. Specifically, we find 53% of unicorns have given their most recent investors either a return guarantees in IPO (14%), the ability to block IPOs that do not return most of their investment (20%), seniority over all other investors (31%), or other important terms.

    Online Appendix is available at https://ssrn.com/abstract=2968003.
     
  5. anonymous

    anonymous Guest

    there is a fierce pharma article on de-horning the unicorns

    Basically these companies stay private because they can't pass the scrutiny of the public markets (i.e. Easier to BS when private)
     
  6. anonymous

    anonymous Guest

    This is total bull. Intarcia is curing compliance with a once a year pump. Totally disruptive in a market where the loser companies develop novel therapeutics that fail right and left. A once a year pump is HUGE... even in China
     
  7. anonymous

    anonymous Guest

    Keep smoking what you're smoking........
     
  8. anonymous

    anonymous Guest

    Stop lying Sparky as there is NO 1-yr implant but 1st year therapy requires 3 implants (starter 3-month, 6-month then 9-month thereafter IF patient is still on it and MCOs are shelling out the big bucks) and not to mention 5 minor surgeries.

    Now what's the word on the street about the possible dreaded down rounds? What's the scoop behind the VCs bailing out last year from this 20-yr old perennial "startup" and sold their shares to the Chinese soon-to-be bagholders?

    And what will you do now that Teva will be marketing the dreaded generic version of the same drug exenatide in 2 months for pittance?
     
  9. WSJ’s Carreyrou talks about how the Theranos story happened
    BY CHRIS ROUSH · FEBRUARY 27, 2017


    [​IMG]
    John Carreyrou

    John Carreyrou, an investigative reporter at The Wall Street Journal, talks about his coverage of the blood testing company Theranos in a short video.

    Carreyrou notes in the video that he began investigating the company after a whistleblower approached him with information about its operations.

    “The blood testing startup wasn’t all that it seemed,” said Carreyrou. “I talked to my editor, Mike Siconolfi, and he agreed we should investigate.”

    Carreyrou then spent months collecting accounts from doctors, patients and whistleblowers. His reporting was made more difficult because of nondisclosure agreements signed by former employees.

    “When we confronted them with our findings, they responded by threatening us with litigation and threatening our sources,” said Carreyrou.

    The Journal ran the story anyway, and Carreyrou has continued to report about the company.

    “The response was explosive,” said Carreyrou. “People woke up to the excesses of the Silicon Valley boom.”
     
  10. anonymous

    anonymous Guest

    2 Unicorns left... Theranos moving to criminal prosecution stage...Intarcia crippled by FDA rejection...Moderna still raising money

    Intarcia in flames - is there a criminal prosecution phase for lying ?

    Moderna in early stage - can’t blow up if you never go to the clinic...when does the bubble pop ?
     
  11. anonymous

    anonymous Guest

    One unicorn left ? Only Moderna ?

    smoking craters mark the burning remains of theranos and intarcia.....
     
  12. anonymous

    anonymous Guest

    Moderna has sooooo much money can run forever

    Aret the other two bankrupt ?
     
  13. anonymous

    anonymous Guest

    $500 Million for largest biotech IPO in history for Moderna. Nothing Approved. Nothing in Phase 3. Nothing in Phase 2. Might have something in Phase 1. No Evidence of Success.

    Rejected by FDA. Raised Billions for Intarcia. Nothing Approved. Nothing Novel. No Evidence of Success.

    On the way to Jail. All the money flushed away for Theranos. Nothing Approved. No Evidence of Success.

    The Three Horsemen Ride A Standard Path. Fools And Their Money Are Soon Parted.

    Extraordinary Popular Delusions and the Madness of Crowds is an early study of crowd psychology by Scottish journalist Charles Mackay, first published in 1841.[1] The book was published in three volumes: "National Delusions", "Peculiar Follies", and "Philosophical Delusions"

    The first volume begins with a discussion of three economic bubbles, or financial manias: the South Sea Company bubble of 1711–1720, the Mississippi Company bubble of 1719–1720, and the Dutch tulip mania of the early seventeenth century. According to Mackay, during this bubble, speculators from all walks of life bought and sold tulip bulbs and even futures contracts on them. Allegedly, some tulip bulb varieties briefly became the most expensive objects in the world during 1637.[6
     
  14. anonymous

    anonymous Guest

    will moderna go public ??
     
  15. anonymous

    anonymous Guest

    why does moderna need money ? they dont have any drugs in Phase 2 or Phase 3 ? just monkey assed preclinical bullshit with fancy slides... why does that cost so much money ?
     
  16. anonymous

    anonymous Guest

    Biggest IPO EVER !! Stephanie is the best CEO !!
     
  17. anonymous

    anonymous Guest

    theranos headed to jail
    Moderna toxic IPO cut in half
    Intarcia headed to bankruptcy

    Is this the three unicorn apocalyptic events foretold by Nostradamus?
     
  18. anonymous

    anonymous Guest

    Moderna has two directors- women that need to be changed. Not only are they too young to fill those roles but their poor attitude altogether. Demeaning to the manuf. group and not motivating. They can learn a thing or two from the others.
     
  19. anonymous

    anonymous Guest

    Yep, what did you expect. One senior ext. manufac. level director woman in particular is well connected to one of the upper executive committee. She's a farce and completely lacks finesse in dealing with the team in her cross functional role. What's going to happen is that people will be leaving as working under her or with her is too overwhelming. Feel like I get tasked with little or no motivation behind it. Uses big words in order to show she knows what's she's doing. People are delegated tasks above paygrade that clearly she should be doing but is sly in getting away with it. Needs better structuring for the level of growth that is needed.
     
  20. anonymous

    anonymous Guest

    Moderna is doing surprisingly well..
    despite leadership— is the tech good?